SCHEMBL5863074

SCHEMBL5863074

CCOC(=O)c1ccc(-c2ccccc2CSCCOc2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
TDP1 Q9NUW8 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KCNH2 Q12809 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
RAB9A P51151 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
ALDH1A1 P00352 2/20 0.42
PTPN1 P18031 1/20 0.42
F2RL3 Q96RI0 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
FFAR1 O14842 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
LMNA P02545 1/20 0.41
EGFR P00533 1/20 0.40
SRC P12931 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863066 0.88 MEN1 (0.50) MAPTTDP1L3MBTL1RAB9AMEN1
SCHEMBL5863080 0.86 CA12 (0.44) MAPTRAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL5863071 0.86 PKM (0.54) ALDH1A1FFAR4
SCHEMBL5863183 0.85 MAPT (0.53) MAPTTDP1L3MBTL1KCNH2HRH3
SCHEMBL5863115 0.84 SMN1; SMN2 (0.49) MAPTTDP1L3MBTL1RAB9AMEN1
SCHEMBL5863106 0.81 TDP1 (0.52) MAPTTDP1L3MBTL1KCNH2HRH3
SCHEMBL5863181 0.80 SMN1; SMN2 (0.47) MAPTTDP1L3MBTL1RAB9AMEN1
SCHEMBL5863083 0.77 ALDH1A1 (0.50) MAPTRAB9AMEN1KMT2APOLB
SCHEMBL27617754 0.77 CA12 (0.47) MAPTRAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL6253221 0.76 FOLH1 (0.50) KMT2AALDH1A1FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132456-B2 MCH receptor antagonists ELI LILLY AND COMPANY (US) 2006-11-07 US disclosed
US-20060052449-A1 Novel mch receptor antagonists ELI LILLY AND COMPANY 2006-03-09 US disclosed
EP-1572637-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-09-14 EP disclosed
WO-2004052848-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052449-A1 Novel mch receptor antagonists MCHR1, MCHR2, MC1R MAPT 1595/4885TDP1 4438/4885L3MBTL1 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.